On July 17, WuXi XDC (02268.HK) fell 3.04% in regular trading to HK$56.25, with turnover of HK$128 million.

On the news front, BOCOM International recently lowered its target price for WuXi XDC to HK$80 while maintaining a Buy rating, citing short-term headwinds. The broker cut 2026-2028 revenue forecasts by 4% and slashed net profit estimates by 15% to 23%, reflecting FX volatility, one-time financial costs from the Dongzhao Pharma acquisition and consolidation, and rising SG&A expenses. Adjusted net profit forecasts were also reduced by 4% to 14%.

The broader Life Sciences Tools and Services sector saw widespread selling pressure on the same session. Among peers, WuXi Biologics fell 4.12%, WuXi AppTec dropped 4.07%, Insilico declined 8.28%, Joinn Laboratories fell 9.99%, and XtalPi lost 5.53%, indicating broad sector weakness compounding the stock-specific downgrade impact.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)